Pure Global

Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service. - Trial NCT06376097

Access comprehensive clinical trial information for NCT06376097 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06376097
Recruiting
Trial Details
ClinicalTrials.gov • NCT06376097
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.
Implementation of a Lung Cancer Screening Program in a Public Service, Using Low-dose Tomography and Metabolomics Evaluation

Study Focus

Lung Cancer

Observational

Sponsor & Location

AstraZeneca

Botucatu, Brazil

Timeline & Enrollment

N/A

Apr 19, 2023

Jan 30, 2025

1000 participants

Primary Outcome

Absolute number and frequency of false-negative lung nodules .

Summary

Observational study that aims to evaluate the implementation of a lung cancer screening
 program in a smoker population included in a public heath service.

ICD-10 Classifications

Carcinoma in situ: Bronchus and lung
Secondary malignant neoplasm of lung
Malignant neoplasm of bronchus and lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm: Overlapping lesion of bronchus and lung

Data Source

ClinicalTrials.gov

NCT06376097

Non-Device Trial